Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07318558 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Study acronym: TroFuse-021
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 163 to 165
  2. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Study sites: 162 to 163 · Eligibility criteria expanded, about 22 words · Secondary endpoints: details revised at 6 of 8 entries Show 3 more changesShow less
    • Study sites: 162 to 163
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 6 of 8 entries
  3. Study sites: 161 to 162v28
  4. Study sites: 159 to 161v27
  5. Trial sites expanded: 155 → 159 locationsv26
  6. Trial sites expanded: 151 → 155 locationsv25
  7. Trial sites expanded: 144 → 151 locationsv24
  8. Trial sites expanded: 138 → 144 locationsv23
  9. Trial sites expanded: 135 → 138 locationsv22
  10. Trial sites expanded: 125 → 135 locationsv21
  11. Trial sites expanded: 118 → 125 locations Eligibility criteria expanded, about 62 words · Secondary endpoints: details revised at 4 of 8 entriesv20 Show 2 more changesShow less
    • Eligibility criteria expanded, about 62 words
    • Secondary endpoints: details revised at 4 of 8 entries

    See this version in full on ClinicalTrials.gov ↗

  12. Trial sites expanded: 115 → 118 locationsv19
  13. Trial sites expanded: 108 → 115 locationsv18
  14. Trial sites expanded: 99 → 108 locationsv17
  15. Trial sites expanded: 89 → 99 locationsv16
  16. Trial sites expanded: 77 → 89 locationsv15
  17. Trial sites expanded: 60 → 77 locationsv14
  18. Trial sites expanded: 50 → 60 locationsv13
  19. Trial sites expanded: 41 → 50 locationsv12
  20. Trial sites expanded: 28 → 41 locationsv11
  21. Trial sites expanded: 24 → 28 locationsv10
  22. Trial sites expanded: 19 → 24 locationsv9
  23. Trial sites expanded: 14 → 19 locationsv8
  24. Study sites: 13 to 14v7
  25. Trial sites expanded: 10 → 13 locationsv6
  26. Study sites: 9 to 10v5
  27. Study sites: 5 to 9v4
  28. Study sites: 2 to 5v3
  29. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Completion date: May 20, 2033 to Feb 25, 2033 · Start date changed from estimate of Feb 25, 2026 to Feb 16, 2026 · 2 morev2 Show 5 more changesShow less
    • Study sites: 0 to 2
    • Completion date: May 20, 2033 to Feb 25, 2033
    • Start date changed from estimate of Feb 25, 2026 to Feb 16, 2026
    • Eligibility criteria expanded, about 38 words
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  30. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
Ovarian Cancer
1,245 trials monitored
See 80 trials at risk
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
Trial Details
NCT Number NCT07318558
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Ovarian Neoplasms, Ovarian Cancer
Enrollment 900 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov